Compare ADMA Biologics Inc (ADMA) vs Best Buy Co Inc (BBY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Best Buy Co Inc — how do they compare? ADMA Biologics Inc trades at $9.26 (market cap $2.13B), while Best Buy Co Inc trades at $78.28 (market cap $16.59B). The key difference: Best Buy Co Inc is far larger — about 7.8× ADMA Biologics Inc's market cap, and Best Buy Co Inc pays a 4.88% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | BBY | |
|---|---|---|
Market Cap | $2.13B | $16.59B |
Sector | Health | Consumer Cyclical |
52-Week High | $20.38 | $84.00 |
52-Week Low | $7.60 | $55.52 |
Enterprise Value | $2.20B | $18.97B |
Dividend Yield | — | 4.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Best Buy (BBY) trades at $78.72, up 0.94% with a bullish technical outlook and positive earnings momentum after beating estimates for three consecutive quarters. The company shows strong profitability with 39.1% ROE and attractive valuation metrics including a 14.44 P/E ratio. Recent leadership transition and strategic focus on higher-margin businesses like marketplace expansion and retail media provide growth catalysts.
The stock offers value with a 5.11% dividend yield and 5% upside to consensus price target of $82.18, though revenue declines and competitive pressures in consumer electronics remain key risks. Analyst sentiment is mixed with 34% buy ratings versus 53% hold, reflecting cautious optimism about the turnaround strategy under new CEO Jason Bonfig.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Best Buy Co Inc
With $51.8 billion in fiscal 2022 sales, Best Buy is the largest pure-play consumer electronics retailer in the U.S., with roughly 10.6% share of the aggregate market and north of 40% share of offline sales, per our calculations, CTA industry, and Euromonitor data. The firm generates the bulk of its sales in-store, with mobile phones and tablets, computers, and appliances representing its three largest categories. Recent investments in e-commerce fulfillment, accelerated by the COVID-19 pandemic, have seen the U.S. e-commerce channel roughly double from prepandemic levels, with management estimating that it will represent a mid-30% proportion of sales moving forward.
Read more on BBY →
